USA - NASDAQ:AADI - US00032Q1040 - Common Stock
The current stock price of AADI is 2.05 USD. In the past month the price decreased by -24.07%. In the past year, price decreased by -5.96%.
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 21.49 | 401.96B | ||
| AMGN | AMGEN INC | 13.39 | 157.25B | ||
| GILD | GILEAD SCIENCES INC | 15.23 | 146.27B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 24.93 | 108.30B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 62.38B | ||
| REGN | REGENERON PHARMACEUTICALS | 14.34 | 69.37B | ||
| ARGX | ARGENX SE - ADR | 90.81 | 51.50B | ||
| INSM | INSMED INC | N/A | 34.94B | ||
| ONC | BEONE MEDICINES LTD-ADR | 5.11 | 34.80B | ||
| NTRA | NATERA INC | N/A | 26.02B | ||
| BNTX | BIONTECH SE-ADR | N/A | 25.25B | ||
| BIIB | BIOGEN INC | 9.31 | 21.86B |
Aadi Bioscience, Inc. operates as a clinical-stage biopharmaceutical company. The company is headquartered in Pacific Palisades, California and currently employs 53 full-time employees. The company went IPO on 2018-06-26. The firm is focused on applying technology to deliver improved precision oncology therapies for people living with difficult-to-treat cancers.
AADI BIOSCIENCE INC
17383 Sunset Avenue, Suite A250
Pacific Palisades CALIFORNIA US
CEO: Joseph Gardner
Employees: 53
Phone: 14244738055
Aadi Bioscience, Inc. operates as a clinical-stage biopharmaceutical company. The company is headquartered in Pacific Palisades, California and currently employs 53 full-time employees. The company went IPO on 2018-06-26. The firm is focused on applying technology to deliver improved precision oncology therapies for people living with difficult-to-treat cancers.
The current stock price of AADI is 2.05 USD. The price decreased by -2.38% in the last trading session.
AADI does not pay a dividend.
AADI has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
AADI BIOSCIENCE INC (AADI) has a market capitalization of 94.85M USD. This makes AADI a Micro Cap stock.
AADI BIOSCIENCE INC (AADI) will report earnings on 2025-05-06, before the market open.
ChartMill assigns a fundamental rating of 2 / 10 to AADI. While AADI seems to be doing ok healthwise, there are quite some concerns on its profitability.
Over the last trailing twelve months AADI reported a non-GAAP Earnings per Share(EPS) of -2.35. The EPS increased by 3.69% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -71.98% | ||
| ROE | -89.57% | ||
| Debt/Equity | 0 |
8 analysts have analysed AADI and the average price target is 3.06 USD. This implies a price increase of 49.27% is expected in the next year compared to the current price of 2.05.
For the next year, analysts expect an EPS growth of 71.14% and a revenue growth -46.53% for AADI